Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ChiCTR2600125057 Pucotenlimab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
ChiCTR2600125057 clinical trial report covering Pucotenlimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07598864 Finerenone Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07598864 clinical trial report covering Finerenone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262015 Human Coagulation Factor IX (Shandong Taibang) Hemorrhage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20262015 clinical trial report covering Human Coagulation Factor IX (Shandong Taibang), Phase 3, endpoints, sponsor, geography, readout timing and developm
Latest Hotspot
8 min read
NCT07604103 Trivalent Influenza virus split vaccine(Sanofi) Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07604103 clinical trial report covering Trivalent Influenza virus split vaccine(Sanofi), Phase 3, endpoints, sponsor, geography, readout timing and develop
Latest Hotspot
8 min read
NCT07605338 Sodium fluoride/triclosan Dental Plaque Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07605338 clinical trial report covering Sodium fluoride/triclosan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07602582 Donanemab-AZBT Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07602582 clinical trial report covering Donanemab-AZBT, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260126 Guselkumab/Golimumab Ulcer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
JPRN-jRCT2031260126 clinical trial report covering Guselkumab/Golimumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071260024 Guselkumab/Golimumab Multiple Hamartoma Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
JPRN-jRCT2071260024 clinical trial report covering Guselkumab/Golimumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07601048 HRS-7058 metastatic non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07601048 clinical trial report covering HRS-7058, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071260031 Envudeucitinib Generalized Pustular Psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
JPRN-jRCT2071260031 clinical trial report covering Envudeucitinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600125401 Nimotuzumab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
ChiCTR2600125401 clinical trial report covering Nimotuzumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-UMIN000061687 Osimertinib mesylate EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
JPRN-UMIN000061687 clinical trial report covering Osimertinib mesylate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.